Affimed Reports Second Quarter 2020 Financial Results and Operational ProgressGlobeNewsWire • 08/11/20
Affimed to Report Second Quarter 2020 Financial Results & Corporate Update August 11, 2020GlobeNewsWire • 08/04/20
Affimed N.V. (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 07/29/20
Affimed's Innate Immune Programs Offer A Compelling Value At Current Price LevelsSeeking Alpha • 07/24/20
Affimed N.V. (AFMD) CEO Adi Hoess on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 06/23/20
Affimed Reports First Quarter 2020 Financial Results and Operational ProgressGlobeNewsWire • 06/23/20
Affimed Announces Presentation of Data on Genentech’s RO7297089 and AFM24, Both Innate Cell Engagers Developed from Affimed’s ROCK® Platform, at AACR Virtual Annual Meeting IIGlobeNewsWire • 06/22/20
Affimed Announces Successful Completion of First Dose Cohort in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other CancersGlobeNewsWire • 06/17/20
Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual MeetingGlobeNewsWire • 05/29/20
Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform Accepted for Presentation at AACR Virtual Annual Meeting IIGlobeNewsWire • 05/15/20
All You Need to Know About Affimed N.V. (AFMD) Rating Upgrade to BuyZacks Investment Research • 04/29/20
Affimed N.V. (AFMD) CEO Adi Hoess on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 04/29/20
Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other CancersGlobeNewsWire • 04/16/20
Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell LymphomaGlobeNewsWire • 04/01/20